Thermo Fisher Scientific is trading $631.65, up 3.02%, as investors rotate toward defensive healthcare shares amid broader market weakness.
- Healthcare gained 1.28% during regular trading amid elevated Treasury yields, oil prices, AI-sector weakness, and uncertainty ahead of the Federal Reserve decision.
- CEO Marc Casper is presenting at Morgan Stanley’s healthcare conference on September 15; no specific new announcement has been reported.
- UBS previously upgraded the stock to Buy and raised its target to $730.